Tempest Therapeutics Inc (TPST)

May 13, 2025

Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com

May 13, 2025

May 13, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025

May 13, 2025

FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan

May 13, 2025

May 11, 2025

Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 11, 2025

May 08, 2025

Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN

May 08, 2025

May 05, 2025

Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace

May 05, 2025

May 05, 2025

Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView

May 05, 2025

May 04, 2025

Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

May 04, 2025

Apr 30, 2025

XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 30, 2025

Apr 29, 2025

Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada

Apr 29, 2025

Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times

Apr 28, 2025

Apr 28, 2025

Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq

Apr 28, 2025

Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan

Apr 28, 2025

Apr 28, 2025

Tempest Therapeutics regains Nasdaq compliance - Investing.com

Apr 28, 2025

Apr 27, 2025

Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX

Apr 27, 2025

Apr 24, 2025

Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE

Apr 24, 2025

Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025

Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025

Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025

Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times

Apr 21, 2025

Apr 19, 2025

Tempest to explore alternatives to advance promising pipeline - The Pharma Letter

Apr 19, 2025

Apr 13, 2025

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN

Apr 13, 2025

Apr 12, 2025

Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025

Apr 12, 2025

HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025

Apr 11, 2025

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable

Apr 11, 2025

Apr 10, 2025

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga

Apr 10, 2025

Apr 10, 2025

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive

Apr 10, 2025

Apr 10, 2025

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com

Apr 10, 2025

Apr 10, 2025

Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance

Apr 10, 2025

Apr 10, 2025

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News

Apr 10, 2025

Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements - Investing.com

Apr 09, 2025

Apr 09, 2025

Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire

Apr 09, 2025

Apr 07, 2025

Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada

Apr 07, 2025

Apr 07, 2025

Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - marketscreener.com

Apr 07, 2025

Apr 07, 2025

Top Analysts Slash Price Targets for Meta Platforms Stock (META) on Macro and Tariff Concerns - The Globe and Mail

Apr 07, 2025

Apr 05, 2025

TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025